GlassScriptPhysician profile
Alejandro I Traveria
NPI 1972571156
$11,746.62
in general payments reported to CMS, 2019-2025
57 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,139 · 2020: $684 · 2021: $1,031 · 2022: $2,058 · 2023: $2,186 · 2024: $1,999 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,834.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,273.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,219.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,199.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,083.75 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Pfizer INC. | $1,003.92 | 2019-2025 | |
| Amgen INC. | $803.63 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $668.08 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $506.34 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $446.45 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $372.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.95 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $242.77 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $239.66 | 2019-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $182.22 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $165.54 | 2024 | Voquezna |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Traveria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.